Arcellx Inc. (NASDAQ:ACLX) shares soared 78.3% in premarket trading Monday after Gilead Sciences (NASDAQ:GILD) revealed plans to acquire the biotechnology company in a transaction valuing its equity ...
Throughout the last three months, 7 analysts have evaluated Arcellx (NASDAQ:ACLX), offering a diverse set of opinions from bullish to bearish. The following table encapsulates their recent ratings, ...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and ...
Arcellx (ACLX) closed down ~17% Monday after privately held Kelonia Therapeutics released early-stage results from a small trial of a CAR-T therapy for multiple myeloma that could have advantages over ...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Bristol Myers Squibb was the first company to win FDA approval for a CAR T-cell therapy for multiple myeloma, and Johnson & Johnson could soon become the second. Arcellx has some catching up to do but ...
-- Median duration of response, progression free survival, and overall survival rate not reached with median follow-up after CART-ddBCMA (anito-cel) infusion of 26.5 months – -- The estimated median ...
Morgan Stanley initiates Arcellx Inc (NASDAQ:ACLX), noting a differentiated CAR-T platform for blood cancer backed by an established CAR-T partner. ddBCMA (aka anito-cel) is Arcellx’s lead asset, ...
On Jan. 20, 2026, Director David Charles Lubner executed the exercise and immediate sale of 6,000 shares of Arcellx, Inc. (NASDAQ:ACLX) common stock for a total transaction value of approximately $450 ...
Arcellx, Inc. is a clinical-stage biotechnology company specializing in innovative immunotherapies for cancer and other incurable diseases. The company primarily works with oncology healthcare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results